Upon examining a skin lesion they suspected of being malignant, few dermatologists—only 8%—would hold back from performing a biopsy if an AI tool disagreed, classifying it as benign.
Upon examining a skin lesion they suspected of being malignant, few dermatologists—only 8%—would hold back from performing a biopsy if an AI tool disagreed, classifying it as benign.